Xeris Biopharma Holdings, Inc.
XERS Nasdaq
SEC CIK 1867096
Follow Xeris Biopharma
Weekly email: filings, results
Revenue, last quarter
$107.2M
+44.2% vs same quarter last year
Net income
$11.3M
+1718% vs same quarter last year
EPS, diluted
$0.06
Operating cash flow
$35.5M
+92.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $291.8M | $554K |
| FY24 | $203.1M | −$54.8M |
| FY23 | $163.9M | −$62.3M |
| FY22 | $110.2M | −$94.7M |
| FY21 | $49.6M | −$122.7M |
| FY20 | $20.2M | −$91.1M |
| FY19 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | 8.5% | 0.2% |
| FY24 | −16.6% | −27% |
| FY23 | −26.8% | −38% |
| FY22 | −74.3% | −85.9% |
| FY21 | −232.2% | −247.5% |
| FY20 | −414.5% | −452.2% |
| FY19 | - | - |
- Xeris Biopharma
- Healthcare median
Show the numbers
| Year | Xeris Biopharma | Healthcare median |
|---|---|---|
| FY25 | 0.2% | −30.6% |
| FY24 | −27% | −47% |
| FY23 | −38% | −58% |
| FY22 | −85.9% | −80.4% |
| FY21 | −247.5% | −71.9% |
| FY20 | −452.2% | −62.2% |
| FY19 | - | −46.3% |